公司资料
ABVC BioPharma, Inc. 股价、新闻与催化剂
- 股票代码:
- ABVC
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States and trades on NASDAQ, placing it in the small-cap biotech category
股票表现
1.01 USD (-0.98%)
收盘价
最后更新: 2026年10月2日
32.5M USD
市值
股价为何变动
截至 2026年10月2日，ABVC 下跌 0.98%，收于 $1.01。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Botanical Drug and Medical Device Developer
ABVC BioPharma develops drug candidates and medical devices originating from botanical compounds and academic research. The portfolio spans central nervous system disorders, oncology, ophthalmology, and women's health.
ABV-1505 for Adult ADHD
ABV-1505 is a botanical drug candidate being studied for adult attention-deficit hyperactivity disorder. The program is intended to offer a non-stimulant treatment approach through a standardized extract and regulated clinical-development pathway.
Vitargus Vitreous Substitute
Vitargus is a bioengineered hydrogel being developed as a vitreous substitute for retinal surgery. The material is designed to maintain the space and optical properties of the eye after removal of the natural vitreous.
Oncology and Additional Programs
The pipeline includes ABV-1519 for non-small cell lung cancer and other botanical candidates licensed from research institutions. Development is conducted through subsidiaries, academic collaborations, and regional clinical partners.
BioFirst Structure
ABVC has organized several development assets through BioFirst and related entities. This structure can support separate financing, partnering, or strategic transactions around individual programs.
未来催化剂
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。